Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Engage Grants Program

Dalhousie University

$24,500.00

Direct Preparation of Key Intermediates in Heterocycle Synthesis Employing Novel Pd-Catalyzed Alpha-Arylation

FY 2011-12

Summary
The majority of pharmaceutical compounds derive their beneficial properties from the presence of a nitrogen-containing heterocyclic core structure. As such, the development of novel routes to such heterocyclic structural motifs, or their direct precursors, represents an important challenge in the quest to advance the drug discovery process. Furthermore, the establishment of synthetic protocols that are efficient and modular in nature, and that exploit cheap and abundant reagents, are particularly attractive in terms of streamlining and diversifying the assembly of heterocyclic core structures, as well as in facilitating reductions in energy consumption and waste (the formation of >25 kilograms of waste for every kilogram of product is commonplace in current pharmaceutical syntheses). This collaborative research project will seek to exploit recent advances in metal-catalyzed synthetic methodology made by the applicant's research group, in addressing specific challenges faced by the industrial partner with regard to the preparation of a promising class of nitrogen-containing heterocyclic compounds. Success in this project will greatly accelerate the industrial partner's drug development program, thereby leading to more rapid identification of novel therapies to the benefit of all Canadians.
Program
Engage Grants Program
Location
Nova Scotia, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data

As published

Application id
428983-2011
Name nom
Stradiotto, Mark
Department département
Chemistry
Organization id
79
Institution établissement
Dalhousie University
Province en
Nova Scotia
Province fr
Nouvelle-Écosse
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2011
Competition year année de concours
2011
Award amount
24500
Program id
EGP
Program nane en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1551
Committee name en
Atlantic Internal Decision Committee
Committee name fr
Comité de décision interne pour l'Atlantique
Area of application code
500
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Manufacturing processes and products
Area of application fr
Procédés et produits industriels
Research subject code
3704
Research subject group en
Organic chemistry
Research subject group fr
Chimie organique
Research subject en
Synthetic methodology
Research subject fr
Méthodologie en synthèse
Partie
1
Nb partie
1
Application title
Direct Preparation of Key Intermediates in Heterocycle Synthesis Employing Novel Pd-Catalyzed Alpha-Arylation
Keyword
NSERC
Application summary
The majority of pharmaceutical compounds derive their beneficial properties from the presence of a nitrogen-containing heterocyclic core structure. As such, the development of novel routes to such heterocyclic structural motifs, or their direct precursors, represents an important challenge in the quest to advance the drug discovery process. Furthermore, the establishment of synthetic protocols that are efficient and modular in nature, and that exploit cheap and abundant reagents, are particularly attractive in terms of streamlining and diversifying the assembly of heterocyclic core structures, as well as in facilitating reductions in energy consumption and waste (the formation of >25 kilograms of waste for every kilogram of product is commonplace in current pharmaceutical syntheses). This collaborative research project will seek to exploit recent advances in metal-catalyzed synthetic methodology made by the applicant's research group, in addressing specific challenges faced by the industrial partner with regard to the preparation of a promising class of nitrogen-containing heterocyclic compounds. Success in this project will greatly accelerate the industrial partner's drug development program, thereby leading to more rapid identification of novel therapies to the benefit of all Canadians.